Safety, Tolerability and Pharmacokinetics of AZD1775 (adavosertib) plus MEDI4736 (durvalumab) in Patients with Advanced Solid Tumours

Trial Identifier:	D6015C00002
Sponsor:	AstraZeneca
NCTID::	NCT02617277
Start Date:	December 2015
Primary Completion Date:	April 2019
Study Completion Date:	December 2024
Condition:	Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
US, CO	Denver, CO, US, 80218
US, FL	Sarasota, FL, US, 34232
US, TN	Nashville, TN, US, 37203

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.